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Summary Parametric models have been suggested as an alternative to conventional life table techniques for
interpretation of observed survival patterns in cancer. This paper extends earlier work on breast cancer by
studying the fit of Boag's lognormal model to the survival of 8,170 breast cancer cases reported to the
Swedish Cancer Registry during 1961-1963. The model was also used to analyse the upward survival trend
for breast cancer cases in Sweden during 1961-1973. The model fitted the 1961-1963 data well for the entire
case material and for patients aged <70 years. It was therefore used to help explain whether the upward
survival trend was due to long term cures or merely to protracted survival with cancer. The estimated cured
proportion among patients aged <70 years rose from 33% +2% (s.e.) during 1961-1963 to 40% +3% for
cases 1971-1973 (P< 0.05). The median survival of uncured cases, was found to be similar during both
periods, 4.5 and 4.6 years respectively. The model did not fit data for patients aged >70 years. It is possibly
too simplistic, and perhaps does not accurately describe the forces of mortality or their interactions in old
patients. Another disadvantage is that large case materials are necessary in order to obtain estimates with
reasonably small standard errors.
As an alternative to the conventional 5- or 10-year
life table survival rates, several authors have
suggested the use ofparametric statistical models to
interpret observed survival patterns in cancer
(Boag, 1948; Berkson & Gage, 1952; Mueller &
Jeffries, 1975; Fox, 1979; Campos, 1972; Haybittle,
1959; 1965). The interest in such models has been
stimulated by claims that they permit, for example,
reliable predictions of long term results from
available short term data, and assessment of
whether an improvement in survival is due to long
term cures or merely to protracted survival with
cancer (Mould & Boag, 1975; Mould et al., 1976).
One of the difficulties with parametric models is
that it is never possible to prove that a particular
model is accurate, but only to reject it if the
predicted values differ significantly from observed
data. Validation of a model should therefore ideally
be based on different populations that include large
numbers of patients with long follow-up.
Two previous investigations concerning patients
with carcinoma cervix uteri and breast cancer have
assessed the relative merits of different models
(Mould & Boag, 1975; Rutqvist et al., 1984). Both
studies showed that Boag's lognormal model
provided the best overall fit to the observed
survival data. For breast cancer, the lognormal
model was the only model which did not show a
significant lack of fit. Both studies were based on
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large case materials but the minimum follow-up
times were fairly short (10 and 6 years respectively).
The present paper extends the earlier work on
breast cancer by studying a population of more
than 8,000 cancer cases from the Swedish Cancer
Registry with follow-up times ranging from 18 to
21 years. The aim of the study was to examine if
the lognormal model fitted the findings on this new
material with longer follow-up, and to assess the
consistency of predictions of long term results from
short term data.
Furthermore an attempt has been made to
validate a 2-parameter lognormal model. Boag's
original model includes 3 parameters which have to
be estimated simultaneously. In order to reduce the
standard errors of the estimates the original model
might be turned into a 2-parameter model by
keeping one of the parameters describing the cancer
specific survival fixed at an assumed value. For
small populations, large standard errors might
otherwise make the estimated parameter values
meaningless.
A report based on cases diagnosed in a limited
geographical area of Sweden has indicated that
there may have been an upward survival trend for
breast cancer during 1961-1973 (Rutqvist, 1984).
Considerable uncertainty exists, however, as to the
proper interpretation of such a trend. It could
simply be due to earlier diagnosis without death
from breast cancer being delayed or avoided (lead
time bias). Such bias might also be a confounding
factor in analyses of age-related differences in
survival. The lognormal model was therefore used
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to interpret the observed survival pattern of cases
reported to the Swedish Cancer Registry during
1961-1963 and 1971-1973 and the results were
compared to those obtained with conventional life-
table techniques.
Materials and methods
Validation ofthe lognormal model
The studied population consisted of 8,170 female
breast cancer cases notified to the Swedish Cancer
Registry during 1961-1963. The respective number
of cases in the age groups <50, 50-69 and . 70y
was 1,934, 3,980 and 2,256. The Cancer Registry is
nation-wide and is based on obligatory reports on
new cancer cases from both clinicians and
pathology/cytology laboratories. The Registry's
coverage of diagnosed breast cancer has been
estimated to 98% (Mattsson & Wallgren, 1984).
Follow-up data were obtained from the Swedish
Registry of Causes of Deaths, which receives
reports on all persons dying in Sweden and on
Swedish citizens who die abroad. Data from the
registry were available on deaths before December
31, 1981. The observation period thus ranged from
18 to 21 years. The observed and relative survival
rates were calculated by means of the life table
method. The relative survival is the ratio between
the observed survival and the expected survival of
an age-matched general population (Ederer et al.,
1961). If the relative survival becomes constant, i.e.
if the survival curve runs parallel to the time axis,
the remaining patients are experiencing a mortality
which is equal to that of a general population and
they are often considered to constitute a cured
group of patients. The expected survival was
derived from life tables for the general Swedish
female population for periods approximately
covering the follow-up period. The standard error
of the relative survival was calculated according to
Ederer et al. (1961).
The Swedish Cancer Registry does not contain
data on tumour stage. The analyses presented here
therefore relate to all cases reported because of
invasive breast cancer.
The lognormal model
This model was originally proposed for cancer
survival by Boag in 1948. It is based on the
observation that survival time distributions in
several malignant diseases are skew with a marked
tail and that the logarithms of the survival times
are approximately normally distributed. The model
assumes that a population of cancer patients
consists of a cured group, c, which is only subject
to normal mortality risks, and an uncured group,
(1-c), which is subject to both the normal
mortality and to a disease-specific mortality. These
two forces of mortality are assumed to act
independently. The survival of a group of patients
in terms of the model can be formulated as:
tPt=Pt{C+(1-C)J a exp-(2)dx}
u=(logt-m)/s
where Pt is the probability to survive to the time t.
Pt is the probability to escape the normal mortality
risk to the time t, m is the mean, and s the standard
deviation of the lognormal survival time distri-
bution. The disease-specific mortality of the
uncured group is thus expressed in terms of the two
parameters m and s. The antilogarithm of m is an
estimate of the median survival of uncured patients.
All three parameters (c, m and s) were estimated
simultaneously with a maximum likelihood method
according to Boag (1949). An iterative procedure
was used starting from rough estimates of the
parameter values which were improved at each
cycle of computation to converge to the solutions.
For the analysis, it was necessary to estimate the
number of deaths attributable to breast cancer
during each yearly interval, i.e. excess deaths. These
deaths were assumed to occur independently. The
number of excess deaths for the year i was
calculated as the difference between the observed
number of deaths during i (Oi) and the expected
number (Ei). Ei was calculated as the product of
the number of woman-years at risk during i (Ni)
and the midpoint estimate of the hazard rate
(instantaneous death rate) from 'normal' causes of
death (ti); N'i=[Ni-(Oi/2)-(WJ/2)], where Ni is
the number of women entering i and Wi the
number withdrawn alive; mi=[qi/(l -qi/2)], where qi
is the conditional probability of dying from
'normal' causes during i; qi=[1 -(Pi/Pi -)], where
Pi is the expected survival at the end of i. Estimates
of P were derived from life tables for the general
Swedish female population for periods approxi-
mately covering the years of follow-up.
It is possible that the maximum likelihood
equations for a particular group of patients cannot
be solved with the mentioned iterative procedure
due to failure of convergence towards any para-
meter values. A conceptually different technique
might then be used: the minimum x2 method.
Starting from rough estimates, the parameter values
are changed stepwise and for each set of estimates,
the theoretical distribution of deaths is compared to
the observed distribution. The deaths are compared
for, e.g. yearly intervals, and a x2 value isUTILITY OF THE LOGNORMAL MODEL 877
computed, the set of estimates yielding the lowest
overall x2 value is selected. These estimates might
differ slightly from those obtained with the
maximum likelihood method depending on the
choice of intervals. With the minimum x2 method,
equal weight is given to each interval of the
observation period for determination of the
parameter values whereas the maximum likelihood
method gives equal weight to each deceased case,
hence intervals with large number of deaths will be
relatively more important. One disadvantage with
the minimum x2 method is that standard errors of
the estimated values cannot be computed.
2-parameter lognormal model
It has been suggested that the standard deviation of
the lognormal model might be kept fixed and only
the two remaining parameters, m and c, kept
floating when solving the maximum likelihood
equations (Boag, 1948; Haybittle, 1959; Mould &
Boag, 1975; Mould et al., 1976). If the number of
patients in an analysis is small, large standard
errors might otherwise make the estimated values
meaningless. The rationale for this technique is that
the standard deviation for a particular disease
might be considered to be a constant. The selected
value of s should preferably be based on data for a
large patient population. For breast cancer, s was
estimated to 0.60log-years in a study including
more than 14,000 patients from the Cancer Registry
of Norway (Rutqvist et al., 1984). However, this
value is lower than the value estimated for all cases
in the 1961-1963 series (0.71 log-years, see Results).
The technique of only two floating parameters was
therefore used, keeping s fixed at either 0.60 log-
years or 0.71 log-years, in addition to Boag's
original technique with three floating parameters.
Testsfor lack offit
A minimum chi-squared test was used to assess the
agreement or disagreement between the observed
survival and the theoretical survival according to
the lognormal model. This method is similar to the
mentioned minimum x2 method for estimation of
parameter values. The estimates obtained with the
maximum likelihood method with either two or
three floating parameters were used in these tests.
The theoretical and observed number of deaths
were compared for yearly intervals. The degrees of
freedom were (n-k-1), where n was the number of
intervals and k the number of estimated para-
meters. A runs test was also performed in order to
detect correlated errors, i.e. a possible non-
randomness of the temporal occurrence of
deviations from the model during the following-up
period.
The survival time trend 1961-1973
The survival time trend during 1961-1973 was
analysed by comparing the results for the
mentioned 1961-1963 series with those for breast
cancer cases reported to the Swedish Cancer
Registry 1971-1973 (n= 10,655).
The statistical significance of differences in
relative survival was tested by comparing the 10
year rates. The parametric analysis using the
lognormal model was restricted to patients aged
below 70 years since the model might not be
applicable for older patients (see Results).
Results
The relative survival of all patients in the 1961-
1963 series is shown in Figure 1. No cured fraction
was observed because the relative survival declined
continuously during the follow-up period, at 20
years it was 41 +1% (s.e.). Figure 2 shows the
material by age at primary diagnosis (<50, 50-69,
.70y). The continuous decline in relative survival
was observed in all age groups. For cases aged
above 70 years, however, the curve showed an
erratic pattern after 15 years which probably was
due to the small number of patients at risk. The
survival was generally higher for young than for
old cases. At 15 years, for instance, the relative
survival for cases aged <50, 50-69 and .70y was
55+1%, 45+1% and 31+3% respectively.
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Figure 1 Relative survival of female breast cancer
cases reported to the Swedish Cancer Registry during
1961-1963 (0, n=8,170) and 1971-1973 (0,
n = 10,655). The 95% confidence intervals are
indicated.
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Figure 2 Relative survival of cases diagnosed 1961-
1963 by age at primary diagnosis. The figures within
parentheses denote the number of cases. The 95%
confidence intervals are indicated.
Table I shows estimates of the parameters of the
lognormal model and their standard errors. All
three parameters were estimated simultaneously
with the maximum likelihood method. The
estimated cured proportion for all cases in the
1961-1963 series was 27+2%, the estimated
median survival of uncured cases was 4.9 years.
The corresponding figures for cases aged <70 years
was 33 +2% and 4.5 years. For the age-group .70
years, no estimates were obtained because the
iterative procedure used for solving the maximum
likelihood equations failed to converge towards any
parameter values.
To assess the relevance of the lognormal model,
tests for goodness-of-fit (minimum x2 test and runs
test) were performed using the estimated parameter
values. The result for all cases is shown in Table II.
The theoretical distribution of deaths did not
deviate significantly (P>0.05) from the observed
distribution and the model could thus not be
rejected. The results for the separate age-groups are
summarized in Table III. No significant deviation
was observed for cases aged <70 years. For the
older patients, the tests were made using parameter
estimates obtained with the minimum x2 method,
but even they yielded a highly significant lack of fit
(P<0.001).
Table IV shows estimates of the parameter values
obtained when using the technique of keeping the
standard deviation fixed. The calculations were
made for all cases in the 1961-1963 series and for
the age-groups <70 and .70 years. As expected,
the standard errors tended to be lower as compared
to those obtained with three floating parameters
(Table I). The estimates showed considerable
variation, however, depending on the value of s.
With s fixed at 0.60 log-years, for instance, the
estimated cure rate for all cases was 34+2% as
compared to 27+2% with s fixed at 0.71 log-years
(P<0.001). The estimated mean, on the other hand,
was significantly higher (P<0.001). The results for
the two age-groups showed similar inconsistencies.
Table I Estimates of parameter values of the lognormal model for female breast
cancer cases by period of primary diagnosis and age. All three parameters (cured
fraction, mean and standard deviation of the lognormal survival time distribution)
were estimated simultaneously with the maximum likelihood method. The figures
within parentheses denote the standard deviation of the parameter value.
Mean of
Period of lognormal Standard
diagnosis, Number Cured distribution Median deviation
age ofcases fraction (log-years) (y) (log-years)
1961-1973:
<70 years 5,914 0.33 (0.02) 0.66 (0.02) 4.5 0.64 (0.01)
<50 years 1,934 0.42 (0.03) 0.73 (0.04) 5.4 0.62 (0.02)
50-69 years 3,980 0.29 (0.02) 0.63 (0.03) 4.3 0.65 (0.02)
>70 years 2,256 NE NE NE
All ages 8,170 0.27 (0.02) 0.69 (0.03) 4.9 0.71 (0.01)
1971-1973:
<70 years 7,070 0.40 (0.03) 0.67 (0.04) 4.6 0.57 (0.02)
<50 years 2,087 0.53 (0.04) 0.62 (0.06) 4.1 0.54 (0.03)
50-69 years 4,983 0.34 (0.04) 0.69 (0.05) 4.9 0.59 (0.02)
NE=no estimates obtained with the maximum likelihood method.
1 no
0Table II Observed deaths during follow-up of 8,170 female
breast cancer cases diagnosed 1961-1963. The theoretical number
of deaths according to the 3-parameter lognormal model. The
parameter values were: cured fraction 0.27, mean of lognormal
distribution 0.69 log-years, and standard deviation 0.71 log-years.
Results from tests of fit between the theoretical and the observed
distribution of deaths (X2 test and runs test).
Year of Observed Theoretical (O-E)2
follow-up deaths (0) deaths (E) E Runs
1 1,179 1,170.4 0.06 -}1
2 867 881.3 0.23 + 2
3 648 648.4 0.00 +
4 520 510.6 0.17 -}3
5 392 419.8 1.85 +-4
6 349 355.5 0.12 +
7 310 301.3 0.25 -}5
8 275 286.6 0.47 +}6
9 245 230.8 0.87 -17
10 190 209.2 1.77 +-
11 183 192.4 0.46 +f8
12 186 178.1 0.35 19
13 171 153.2 2.07 -
14 135 140.0 0.18 +}10
15 136 130.7 0.22 -
16 126 122.1 0.13 - l
17 115 114.6 0.00 -
18 113 108.7 0.17 -J
19 75 89.0 2.20 +-
20 52 53.8 0.06 +'12
21 10 15.0 1.67 +J
Total 6,277 6,311.5 13.31 12
X2 (l7df)=13.31, P>0.05.
Number of runs= 12, P>0.05.
Table III Summary of results from the tests of fit
between the theoretical distribution and the
observed distribution of deaths in the 1961-1963
series. 0 signifies that the lognormal model was
rejected because the minimum x2 test and/or the
runs test showed a significant (P<0.05) lack of fit,
+ signifies that the model was not rejected.
Resultfrom
Type ofmodel and case material tests offit
3-parameter model
<50 years +
50-69 years +
>70 years oa
All ages +b
2-parameter model,
standard deviation 0.60 log-years
<70 years 0
>70 years 0
All ages 0
2-parameter model,
standard deviation 0.71 log-years
<70 years 0
. 70 years 0
All ages +
aEstimates of the parameter values obtained with
the minimum x2 method; bresults shown in Table
II.
Table IV Estimates of parameter values of the lognormal
model for all cases and for those aged above 70 years in
the 1961-1963 series. The standard deviation was kept
fixed at either 0.60 log-years. The remaining two
parameters were estimated with the maximum likelihood
method. The figures within parentheses denote the
standard deviation of the parameter value.
Mean of
Fixed value of lognormal
standard deviation Cured distribution Median
and age fraction (log-years) (y)
0.60 log-years:
<70 years 0.36 (0.01) 0.62 (0.01) 4.2
. 70 years 0.26 (0.04) 0.51 (0.02) 3.2
All ages 0.34 (0.02) 0.58 (0.01) 3.8
0.71 log-years:
<70 years 0.29 (0.01) 0.73 (0.02) 5.4
. 70 years -0.06 (0.04) 0.91 (0.04) 8.0
All ages 0.27 (0.01) 0.69 (0.01) 4.9
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Table III summarizes the tests for goodness-of-fit
of the 2-parameter lognormal model, the parameter
values were those shown in Table IV. This model
was only accepted for all cases with s fixed at 0.71
log-years. The model was rejected for the two age-
groups with either value of s, and for all cases with
s fixed at 0.60 log-years.
The parameter values (3-parameter model) for all
cases in the 1961-1963 series were estimated using
survival data for only 5, 10 and 15 years of follow-
up (Table V'). The estimates obtained with the 10-
and 15-year data were similar to those obtained
with data for the entire follow-up period even
though the standard errors were slightly higher.
The 5-year estimates, on the other hand, deviated
considerably. The estimated cured fraction, for
instance, was 41 +6% as compared to 27+2% with
the 18-21 year data (P<0.05).
The survival time trend 1961-1973
Figure 3 shows the relative survival of all patients
by period of diagnosis. The survival at 10 years was
52+ 1% (s.e.) for the 1961-1963 series, and 54 + 1%
for the 1971-1973 series (P<0.05). Further analysis
by age (<50, 50-69, _70y) showed that the
increase at 10 years was only significant for the
age-group 50-69 years for which it rose from
49+1% to 54+1% (P<0.001) (Figure 2). For
patients aged <50 years and >70 years, the
increases were smaller, 12-3%, and not
statistically significant (Figures 4 and 5).
Table I shows estimates of the 3 parameters of
the lognormal model and their standard errors for
cases aged <70 years by period of diagnosis and by
age (<50, 50-69y). Older patients were excluded
from the analysis because of the mentioned poor fit
of the model. The estimated cured proportion rose
from 33% in the 1961-1963 series to 40% in the
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Figure 3 Relative survival of cases aged 50-69 years
by period of diagnosis. (0) 1961-1963, n=3,980; (@)
1971-1973, n=4,983. The 95% confidence intervals are
indicated.
1971-1973 series (P<0.05). The estimated mean of
the lognormal distribution, on the other hand, was
similar in both series: 0.66 log-years (4.5y) and 0.67
log-years (4.6y).
Significant increases (P<0.05) of the estimated
cured fraction were observed both for cases aged
below 50 years (42% to 53%) and 50-69 years
(29% to 34%). The estimated cured proportion was
thus consistently higher for the younger cases in
both series. The estimated median survival of
uncured cases, however, was not significantly
different between the two age-groups during either
period.
Table V Estimates of parameter values of the 3-parameter
lognormal model for the 1961-1963 series. The estimates were
obtained with the maximum likelihood method using data for
various lengths of follow-up. The figures within parentheses denote
the standard error of the parameter value.
Mean of
lognormal Standard
Years of Cured distribution Median deviation
follow-up fraction (log-years) (y) (log-years)
5 0.41 (0.06) 0.50 (0.09) 3.2 0.61 (0.04)
10 0.26 (0.04) 0.70 (0.05) 5.0 0.72 (0.02)
15 0.26 (0.01) 0.70 (0.04) 5.0 0.72 (0.02)
18-21 0.27 (0.02) 0.69 (0.03) 4.9 0.71 (0.01)UTILITY OF THE LOGNORMAL MODEL 881
models include the cured proportion of patients and
differ only in the analytical form of the disease-
specific survival for non-cured cases. The cured
proportion is in this context defined as the
proportion of patients who experience a death rate
from all causes of death which is similar to that of
an age-matched general population. As mentioned
earlier, it is not possible to prove that any model is
true. It is only possible to reject it if it can be
shown that the theoretical survival according to the
model significantly deviates from the observed
survival in a studied population. Tests for
goodness-of-fit are therefore more reliable when
based on large case materials. It is understandable
that different models have been suggested in the
literature since they were often established on fairly
restricted data.
In two previous investigations it was shown that
Boag's lognormal model provided the best overall
fit to the observed survival data for carcinoma
-,;.-+: --A r_ _^ fkx-w..IA P. 'D_
Figure 4 Relative survival of cases ag
by period of diagnosis. (0) 1961-1963,
1971-1973, n=2,087. The 95% confidenc
indicated.
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Figure 5 Relative survival of cases ag
by period of diagnosis. (0) 1961-1963,
1971-1973, n=3,585. The 95% confidenc
indicated.
Discussion
The interest in parametric survival
mainly focused on relatively simple
functions with 2 or 3 parameters. T]
are usually assumed to have biolog
and thus to be clinically meaningful.
YEARS cervix uteri ana tor breast cancer (Moula & Doag,
red <50 years 1975; Rutqvist et al., 1984). The other studied
n=1,934; (0) models, including the 'extrapolated actuarial', the
e intervals are Weibull and various exponential models, were
either rejected or were found to yield less consistent
results. The current study also failed to disclose a
siianificant lack of fit with the loanormal model
except for cases aged above 70 years. The model
was rejected for this age group. There are several
possible reasons for the lack of fit. It has, for
instance, been reported that erroneous registration
of old breast cancer cases was common in the
Swedish Cancer Registry during the early 1960s. In
the age-group >70 years, it was estimated that
about 7% of the total number of cases should be
excluded from the registry files because of
registration errors (Rutqvist & Wallgren, 1983).
These cases were mostly patients with recurrences
from breast cancer diagnosed during previous years,
and hence poor survival. Among younger women,
such errors were found to be less frequent. If
erroneous cases had been excluded from the current
study, it is possible that the fit of the lognormal
model would have been better. On the other hand,
tne mouei mignt oe too simplistic, ano pernaps
does not accurately describe the forces of mortality
ed .70 years or their interactions in old breast cancer patients.
n =2,256; (0) The model assumes that death from intercurrent
,e intervals are causes and from breast cancer occur independently
but this assumption might not hold good. In old
patients, debilitating conditions such as chronic
heart and lung diseases might hasten death from
disseminated breast cancer thereby producing
I models has deviations from the model. Nevertheless, in view of
mathematical the fact that the model could not be rejected for all
he parameters cases nor for cases aged less than 70 years (Table
ical correlates III), it seemed to provide fairly good approxi-
Many of the mations of breast cancer survival. Theoretically it is
v ;a
I--
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attractive because it is consistent both with late
excess mortality and with a cured fraction.
Estimates of parameter values based on follow-
up data for 10 years were similar to those obtained
using data for the entire follow-up period (Table
V). This suggests that the model could be used for
prediction of long term results from short term
data. However, the relative survival declined during
the entire follow-up period (Figure 1) and a cured
fraction could not be observed. Hence, extra-
polations from the model should be cautiously
judged until supported by observed data.
One disadvantage with the lognormal model is
that large populations are necessary in order to
obtain stable estimates of the parameter values. The
95% confidence interval of the estimated cured
proportion for cases aged less than 50 years in the
1961-1963 series, for instance, was found to be 36-
47% even though this group consisted of more than
1,900 cases. In order to reduce the standard errors,
Boag suggested that the standard deviation of the
model might be kept fixed and only the remaining
two parameters be estimated. The original 3-
parameter model is thus converted into a less
flexible 2-parameter model. The rationale for this
technique is that the standard deviation might be
considered as a constant for a given disease, and
was supported by the finding that estimates of the
cured proportion were similar even with fairly large
variations in the assumed value of the standard
deviation (Mould & Boag, 1975). This result was
based on studies on carcinoma cervix uteri and on
head and neck cancers. However, the estimated
value of the standard deviation in the current study
(0.71 log-years) was not similar to that estimated in
a previous study (0.60 log-years) based on more
than 14,000 breast cancer cases from the
Norwegian Cancer Registry (Rutqvist et al., 1984).
Furthermore, estimates of the cured proportion and
the mean of the lognormal distribution were
significantly different when the standard deviation
was fixed at 0.60 log-years as compared to 0.71 log-
years (Table IV). Similar findings were reported by
Haybittle (1959). Tests for goodness-of-fit also
disclosed significant deviation with the standard
deviation fixed at 0.60 log-years (Table III). In view
of these inconsistencies the present results support
Haybittle's conclusion that the 2-parameter
lognormal model is not advisable for analysis of
breast cancer survival. The standard deviation is
probably affected by the stage distribution and thus
probably varies from one case material to another.
Therefore, no a priori assumption of its value is
possible. The reason why some of the previous
studies did not produce significant deviations could
be that the case materials were smaller or that the
studied populations were more homogeneous with
regard to disease outcome than is usually the case
in breast cancer.
This study confirmed previous information
(Rutqvist, 1984) by showing an upward survival
trend for breast cancer in Sweden during 1961-
1973. The trend was unequally distributed and was
only significant for cases aged 50-69 years. The
relative survival of patients aged below 50 years
and above 70 years showed only minor,
insignificant increases. The potential problem of
lead time bias should, however, be considered when
judging the survival trend. Unfortunately no
methods are at present available which permit
determination of lead time differences between
patient populations diagnosed during different
periods.
Lead time bias is not a confounding factor if the
outcome of treatment is measured in terms of the
proportion of patients who are cured. In the
current study, the relative survival declined during
the entire follow-up period and a cured group of
patients could not be observed. This finding
accords with many other long term follow-up
studies which have shown that the excess mortality
from breast cancer probably persists at least up to
30-40 years after diagnosis (Adair et al., 1974;
Baum, 1976; Rutqvist & Wallgren, 1985). The
higher relative survival for more recently diagnosed
cases (Figure 1) and for young as compared to old
cases (Figure 2) might therefore be explained by
lead time bias.
To get round this problem, the lognormal model
was utilized to interpret the observed survival
patterns. According to the model, the survival trend
was the result of a 7% increase (95% confidence
interval: 0-13%, P<0.05) of the cured proportion.
The estimated median survival of uncured cases, on
the other hand, was similar during 1961-1963 and
1971-1977 (4.5 and 4.6 years). This result suggests
that the trend was the result of long-term cures and
not merely due to protracted survival with cancer.
Similarly the higher relative survival rates for young
as compared to old patients were also reflected in
higher estimated proportions of cures.
Breast cancer incidence rates have increased in
most countries in the Western world during the
past decades. It has been suggested that this could
be the result of an increased diagnosis of
'biologically benign' breast cancer, i.e. breast lumps
exhibiting all histologic characteristics of cancer,
but which have relatively benign biological
properties (Fox, 1979; Doll & Peto, 1981). An
increased proportion of patients with such lesions
among the more recently diagnosed cases might
explain an increased proportion of 'cured cases' and
consequently also an upward survival trend. Due to
the limited data on the natural time history ofUTILITY OF THE LOGNORMAL MODEL 883
breast cancer, it is not known whether 'biologically
benign' breast cancers exist, nor if they have biased
the incidence trend. It therefore remains
controversial whether the survival trend reported
here, is the result of an improved outcome for
patients with serious breast cancer or if it is simply
artifactual.
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